Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMSA-101 by ImmuneSensor Therapeutics for Uveal Melanoma: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...
IMSA-101 by ImmuneSensor Therapeutics for Metastatic Renal Cell Carcinoma: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
IMSA-101 by ImmuneSensor Therapeutics for Hematological Tumor: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Hematological Tumor. According to GlobalData, Phase...
IMSA-101 by ImmuneSensor Therapeutics for Metastatic Melanoma: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
IMSA-101 by ImmuneSensor Therapeutics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
IMSA-101 by ImmuneSensor Therapeutics for Metastatic Breast Cancer: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
IMSA-101 by ImmuneSensor Therapeutics for Head And Neck Cancer: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Head And Neck Cancer. According to...
IMSA-101 by ImmuneSensor Therapeutics for Solid Tumor: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
IMSA-101 by ImmuneSensor Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
IMSA-101 by ImmuneSensor Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
IMSA-101 by ImmuneSensor Therapeutics for Solid Tumor: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
IMSA-101 by ImmuneSensor Therapeutics for Renal Cell Carcinoma: Likelihood of Approval
IMSA-101 is under clinical development by ImmuneSensor Therapeutics and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...